| Kempers, Steven |
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita |
|
|
| Recruiting | 3 | 80 | Europe, US | QTORIN 3.9% rapamycin anhydrous gel, Vehicle | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 06/23 | 06/23 | | |
NCT05643872: A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita |
|
|
| Recruiting | 3 | 45 | US | PTX-022 | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 10/23 | 11/23 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 07/25 | 06/26 | | |
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) |
|
|
| Completed | 2 | 199 | US | NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel | NFlection Therapeutics, Inc. | Cutaneous Neurofibroma, Neurofibromatosis 1 | 10/23 | 10/23 | | |
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis |
|
|
| Recruiting | 2 | 60 | US | SM-020 gel 1.0%, Vehicle gel | DermBiont, Inc. | Seborrheic Keratosis | 09/24 | 10/24 | | |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
| Kempers, Steve |
SELVA, NCT06239480: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations |
|
|
| Recruiting | 3 | 40 | US | QTORIN 3.9% Rapamycin Anhydrous Gel | Palvella Therapeutics, Inc. | Microcystic Lymphatic Malformation | 01/26 | 07/26 | | |
| Mohseni, Rizwana |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 06/25 | 06/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 09/25 | 09/27 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Recruiting | 2 | 261 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 09/24 | 10/24 | | |
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
|
|
| Recruiting | 2 | 204 | US | HU6, Placebo | Rivus Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver | 02/25 | 04/25 | | |
| Recruiting | 2 | 48 | US | GSK4532990 | GlaxoSmithKline | Non-alcoholic Fatty Liver Disease | 06/25 | 06/25 | | |
NCT05936151: A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | LY3437943, Placebo | Eli Lilly and Company | Overweight or Obesity, CKD, Type 2 Diabetes | 11/25 | 11/25 | | |
NCT05864391: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. |
|
|
| Terminated | 1 | 40 | US | AZD7503 | AstraZeneca | Steatohepatitis | 03/24 | 03/24 | | |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
| Horita, Allie |
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) |
|
|
| Completed | 2 | 199 | US | NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel | NFlection Therapeutics, Inc. | Cutaneous Neurofibroma, Neurofibromatosis 1 | 10/23 | 10/23 | | |
NCT06393452: Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA |
|
|
| Recruiting | 2 | 60 | US | PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel | Pelage Pharmaceuticals, Inc. | Androgenetic Alopecia | 12/24 | 02/25 | | |
| Skrei, Jenjira |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
| Elliott, Buffi |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
| Stephany, Moreno |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
| Gamal-Edlin, Aisha |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
| Bautista, Cynthia Sanchez |
NCT06393452: Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA |
|
|
| Recruiting | 2 | 60 | US | PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel | Pelage Pharmaceuticals, Inc. | Androgenetic Alopecia | 12/24 | 02/25 | | |
| Roosendaal, Kadie Van |
NCT06393452: Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA |
|
|
| Recruiting | 2 | 60 | US | PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel | Pelage Pharmaceuticals, Inc. | Androgenetic Alopecia | 12/24 | 02/25 | | |
